Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
temozolomide + cisplatin + nivolumab
- Development stage
- Unknown
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination therapy consists of the alkylating agent temozolomide, the platinum-based chemotherapy cisplatin, and the PD-1 checkpoint inhibitor nivolumab. It is being investigated in a Phase II clinical trial led by Memorial Sloan Kettering Cancer Center for the treatment of advanced or metastatic mismatch repair-proficient (MMR-proficient) colorectal adenocarcinoma. Cisplatin works by forming DNA cross-links, temozolomide is an oral alkylating agent that causes DNA damage, and nivolumab is a monoclonal antibody that blocks the PD-1 receptor on T cells, enhancing the immune response against tumor cells. The combination aims to overcome the traditional resistance of MMR-proficient colorectal cancer to immunotherapy by using chemotherapy to potentially increase tumor immunogenicity and alter the tumor microenvironment.
- Brand names
- OpdivoPlatinolTemodar
- Other names
- TMZ + cisplatin + nivolumabtemozolomide + cisplatin + nivolumab combination
02
Targets
DNAPDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on temozolomide + cisplatin + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on temozolomide + cisplatin + nivolumab.